No definite difference for primary endpoint but proven safety with ARNI in MI patients - PACE-CME

No definite difference for primary endpoint but proven safety with ARNI in MI patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Renal denervation as option for patients with hypertension despite medications
Renal denervation as option for patients with hypertension despite medications
ACC.21
Renal denervation as option for patients with hypertension despite medications
- Prof. Ajay Kirtane, MD
No superiority with NOAC compared to standard care following TAVI
No superiority with NOAC compared to standard care following TAVI
ACC.21
No superiority with NOAC compared to standard care following TAVI
- Jean-Philippe Collet, MD, PhD
A call to solve the controversy on omega-3FAs trials
A call to solve the controversy on omega-3FAs trials
ACC.21
A call to solve the controversy on omega-3FAs trials
- Prof. Eileen Handberg, PhD
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
ACC.21
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
- William Schuyler Jones, MD